Use of Yttrium-90 Microspheres (Therasphere®) in a Patient with Unresectable Hepatocellular Carcinoma Leading to Liver Transplantation

Citations Over TimeTop 10% of 2005 papers

Abstract

Prior to therapy, model for end stage liver disease (MELD) scoring, diagnostic imaging and tumor staging were performed in a patient with T3 HCC. The patient received an orthotopic liver transplant (OLT) 42 days after treatment. The explant specimen showed complete necrosis of the target tumor. Follow-up of this patient has demonstrated no evidence of recurrence. There was no life threatening or fatal adverse experiences related to treatment. This case report documents the natural course, history and outcome of a patient treated with yttrium-90 for unresectable HCC. The patient was downstaged from T3 to T2 and was subsequently transplanted.

Related Papers

• → Is severe progressive liver disease caused by alpha‐1‐antitrypsin deficiency more common in children or adults?(2016)45 cited
• → Exam 2: Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria(2012)9 cited
• → Expanding the Limits of Liver Transplantation for Hepatocellular Carcinoma(2020)8 cited
• Treatment of hepatocellular carcinoma by orthotopic liver transplantation:Report of 3 cases(2004)
• → Advances in the application of model for end-stage liver disease and MELD-Na scores in liver transplantation(2019)